Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-02-27

FDA Approved: CABENUVA — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

The FDA approved a supplemental application for CABENUVA, the long-acting HIV-1 treatment regimen of cabotegravir and rilpivirine, filed by ViiV Healthcare Comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CABENUVA (cabotegravir and rilpivirine)

Snippet

SUPPL AP for CABENUVA (CABOTEGRAVIR AND RILPIVIRINE)